| Literature DB >> 29848663 |
Haixia Yang1,2, Weicang Wang1, Kymberleigh A Romano3, Min Gu1, Katherine Z Sanidad1,4, Daeyoung Kim5, Jun Yang6, Birgitta Schmidt7, Dipak Panigrahy8, Ruisong Pei9, Derek A Martin9, E Ilker Ozay4,10, Yuxin Wang1,11, Mingyue Song1, Bradley W Bolling9, Hang Xiao1,4, Lisa M Minter4,10, Guang-Yu Yang12, Zhenhua Liu4,13, Federico E Rey14, Guodong Zhang15,4.
Abstract
Triclosan (TCS) is a high-volume chemical used as an antimicrobial ingredient in more than 2000 consumer products, such as toothpaste, cosmetics, kitchenware, and toys. We report that brief exposure to TCS, at relatively low doses, causes low-grade colonic inflammation, increases colitis, and exacerbates colitis-associated colon cancer in mice. Exposure to TCS alters gut microbiota in mice, and its proinflammatory effect is attenuated in germ-free mice. In addition, TCS treatment increases activation of Toll-like receptor 4 (TLR4) signaling in vivo and fails to promote colitis in Tlr4-/- mice. Together, our results demonstrate that this widely used antimicrobial ingredient could have adverse effects on colonic inflammation and associated colon tumorigenesis through modulation of the gut microbiota and TLR4 signaling. Together, these results highlight the need to reassess the effects of TCS on human health and potentially update policies regulating the use of this widely used antimicrobial.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29848663 PMCID: PMC6343133 DOI: 10.1126/scitranslmed.aan4116
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956